Old Web
English
Sign In
Acemap
>
authorDetail
>
Xiaolin Dong
Xiaolin Dong
Shandong University
Type 2 diabetes
Medicine
Internal medicine
Endocrinology
Randomized controlled trial
4
Papers
57
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
DUAL II China: Superior HbA1c reductions and weight loss with insulin degludec/liraglutide (IDegLira) versus insulin degludec in a randomized trial of Chinese people with type 2 diabetes inadequately controlled on basal insulin.
2021
Diabetes, Obesity and Metabolism
Yu Pei
Bue R. Agner
Bin Luo
Xiaolin Dong
Dongmei Li
Jun Liu
Lei Liu
Ming Liu
Yibing Lu
Tomoyuki Nishida
Xiangjin Xu
Yiming Mu
Show All
Source
Cite
Save
Citations (0)
Efficacy and safety of once-weekly semaglutide vs once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes (SUSTAIN China): a 30-week double-blind, phase 3a, randomised trial.
2020
Diabetes, Obesity and Metabolism
Linong Ji
Xiaolin Dong
Yiming Li
Yufeng Li
Soo Lim
Ming Liu
Zu Ning
Søren Rasmussen
T. V. Skjøth
Guoyue Yuan
Freddy G. Eliaschewitz
Show All
Source
Cite
Save
Citations (6)
Efficacy and Safety of Insulin Glargine 300 U/mL versus Insulin Glargine 100 U/mL in Asia Pacific Insulin‐Naïve People with Type 2 Diabetes: The EDITION AP Randomised Controlled Trial
2019
Diabetes, Obesity and Metabolism
Linong Ji
Eun Seok Kang
Xiaolin Dong
Ling Li
Guoyue Yuan
Shuhua Shang
Elisabeth Niemoeller
Edition Ap trial investigators
Show All
Source
Cite
Save
Citations (5)
Efficiency of anthropometric indicators of obesity for identifying cardiovascular risk factors in a Chinese population.
2011
Postgraduate Medical Journal
Xiaolin Dong
Yang Liu
Jie Yang
Yu Sun
Li Chen
Show All
Source
Cite
Save
Citations (46)
1